Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14700172 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL1565807 | 0.75 | ENPEP (0.47) | MEN1CYP1A2KMT2ATSHRHIF1A | |
| SCHEMBL2934222 | 0.74 | — | — | |
| SCHEMBL23961069 | 0.74 | NOS3 (0.32) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL11792284 | 0.74 | — | — | |
| SCHEMBL4108080 | 0.74 | — | — | |
| SCHEMBL22122969 | 0.74 | GFPT1 (0.32) | — | |
| SCHEMBL19371887 | 0.74 | GFPT1 (0.32) | — | |
| SCHEMBL11981656 | 0.74 | ANPEP (0.50) | MEN1KMT2A | |
| SCHEMBL393844 | 0.72 | GFPT1 (0.46) | CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | RNMT, RNGTT, CAPG | MEN1 3586/4885CYP1A2 4135/4885KMT2A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.